Found 13 matching trials
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
PHASE3This is a phase III, multi-Center, randomized, placebo-controlled trial to ...
Location
Beijing Cancer Hospital
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
PHASE3This is a multi-center, randomized, double-blind, phase III study to evalua...
Location
Shanghai Pulmonary Hospital
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
PHASE2This is a multicenter, single-arm phase II study to evaluate the efficacy a...
Location
Beijing Cancer Hospital
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
PHASE3The purpose of this study is to evaluate the efficacy and safety of sugemal...
Location
Multiple Locations
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
PHASE1A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in C...
Location
West China Hospital, Sichuan University
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
PHASE1This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expan...
Location
Beijing Cancer Hospital
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
PHASE2This is a multicenter, single-arm, phase II study to evaluate the efficacy ...
Location
Peking University Third Hospital
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
PHASE3This is a randomized, double-blind, placebo-controlled, multicenter phase I...
Location
Guangdong Provincial People's Hospital
A Study of CS1001 in Subjects with Advanced Solid Tumors
PHASE1This is a phase I, open-label, multiple-dose, dose-escalation study to eval...
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
PHASE1This is a multicenter, open-label study of CS1001 in combination with regor...
Location
Ashford Cancer Centre Research